Mediation of β-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats

Dar Ming Lai, Yong Kwang Tu, I. Min Liu, Pei Feng Chen, Juei Tang Cheng

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma β-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid μ-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid μ-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid μ-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in β-endorphin secretion that activates opioid μ-receptors thereby resulting in an increased expression of GLUT 4.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalPlanta Medica
Volume72
Issue number1
DOIs
Publication statusPublished - Jan 1 2006
Externally publishedYes

Fingerprint

Endorphins
endorphins
streptozotocin
Streptozocin
Rats
narcotics
Plasmas
Glucose
Opioid Receptors
glucose
rats
glucose transporters
receptors
Facilitative Glucose Transport Proteins
naloxone
Panax ginseng
Ginsenosides
mice
Panax
dosage

Keywords

  • β-endorphin
  • Ginsenoside Rh2
  • Opioid μ-receptor
  • Streptozotocin-induced diabetic rats

ASJC Scopus subject areas

  • Plant Science
  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Mediation of β-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. / Lai, Dar Ming; Tu, Yong Kwang; Liu, I. Min; Chen, Pei Feng; Cheng, Juei Tang.

In: Planta Medica, Vol. 72, No. 1, 01.01.2006, p. 9-13.

Research output: Contribution to journalArticle

Lai, Dar Ming ; Tu, Yong Kwang ; Liu, I. Min ; Chen, Pei Feng ; Cheng, Juei Tang. / Mediation of β-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. In: Planta Medica. 2006 ; Vol. 72, No. 1. pp. 9-13.
@article{2d690b9513d74e689a0e449fb0b6be2b,
title = "Mediation of β-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats",
abstract = "We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma β-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid μ-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid μ-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid μ-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in β-endorphin secretion that activates opioid μ-receptors thereby resulting in an increased expression of GLUT 4.",
keywords = "β-endorphin, Ginsenoside Rh2, Opioid μ-receptor, Streptozotocin-induced diabetic rats",
author = "Lai, {Dar Ming} and Tu, {Yong Kwang} and Liu, {I. Min} and Chen, {Pei Feng} and Cheng, {Juei Tang}",
year = "2006",
month = "1",
day = "1",
doi = "10.1055/s-2005-916177",
language = "English",
volume = "72",
pages = "9--13",
journal = "Planta Medica",
issn = "0032-0943",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - Mediation of β-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats

AU - Lai, Dar Ming

AU - Tu, Yong Kwang

AU - Liu, I. Min

AU - Chen, Pei Feng

AU - Cheng, Juei Tang

PY - 2006/1/1

Y1 - 2006/1/1

N2 - We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma β-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid μ-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid μ-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid μ-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in β-endorphin secretion that activates opioid μ-receptors thereby resulting in an increased expression of GLUT 4.

AB - We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma β-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid μ-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid μ-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid μ-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in β-endorphin secretion that activates opioid μ-receptors thereby resulting in an increased expression of GLUT 4.

KW - β-endorphin

KW - Ginsenoside Rh2

KW - Opioid μ-receptor

KW - Streptozotocin-induced diabetic rats

UR - http://www.scopus.com/inward/record.url?scp=32644455714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32644455714&partnerID=8YFLogxK

U2 - 10.1055/s-2005-916177

DO - 10.1055/s-2005-916177

M3 - Article

VL - 72

SP - 9

EP - 13

JO - Planta Medica

JF - Planta Medica

SN - 0032-0943

IS - 1

ER -